Open Journal Systems

Effect of short-term high-dose atorvastatin on apoE-/-mouse atherosclerosis model

Wei Yang, Chao He, Zaiqiang Zhang, Hui Wu1, Lin Teng, Jiawang Ding

Article ID: 1912
Vol 3, Issue 1, 2022

DOI: https://doi.org/10.54517/ccr.v3i1.1912
VIEWS - 41 (Abstract)

Abstract

Objective: To explore the intervention mechanism of short-term high-dose atorvastatin on atherosclerotic (as) plaque. Methods: 4-week-old male apoE^-/-mouse were fed with high fat for 6 weeks to establish as model. They were randomly divided into control group, model group, atorvastatin conventional dose group, medium dose group and high dose group (load dose group and non load dose group). After 2 weeks, the blood lipid level, inflammatory factor concentration, platelet number, platelet membrane protein expression level and plaque area of each group were compared. Results: Compared with the model group, HDL-C increased significantly, LDL-C decreased significantly, the levels of inflammatory factors in serum and plaque decreased significantly, PLT decreased significantly, and the fluorescence intensity of CD31 and CD62p decreased significantly (all P < 0.05); The level of ox LDL in the load dose group was significantly lower than that in the model group (P < 0.05). The plaque area of atorvastatin intervention groups was significantly lower than that of model group (all P < 0.05). Conclusion: Short-term high-dose atorvastatin may intervene as by reducing blood lipid level, inhibiting the release of related inflammatory factors and regulating the number of platelets and the expression of platelet membrane protein.

Keywords

atherosclerosis; atorvastatin; inflammatory factor

Full Text:

PDF

References

1. Bondonno CP, Blekkenhorst LC, Prince RL, et al. Association of vegetable nitrate intake with carotid atherosclerosis and ischemic cerebrovascular disease inol- derwomen. Stroke, 2017, 48(7): 1724-1729.

2. Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamy transferase and the risk of atherosclerosis and coronary heart disease. Clin Chim Acta, 2018, 476: 130-138.

3. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352 (14): 1425-1435.

4. Mancini G, Martins WC, de Oliveira J, et al. Atorvas- tatin improves mitochondrial function and prevents oxidative stress in Hippocampus following amyloid-pi-40 intracerebroventricular administration in mice. Mol Neurobiol, 2020, 57(10): 4187-4201.

5. Yang X, Xiong T, Ning D, et al. Long-term atorvasta- tin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity. Toxicol Appl Pharmacol, 2020, 402: 115132.

6. Guo H, Xu F, Lv H, et al. Hyperhomocysteine- mia independently causes and promotes atherosclerosis inLDL receptor-deficient mice. J Geriatr Cardiol, 2014, 11(1): 74-78.

7. Ding H. Experimental Pharmacology. Beijing: Science Press, 2008: 1316.

8. Li X, Xiao H, Lin C, et al. Synergistic effects of liposomes encapsulating atorvastatin calcium and curcu- min and targeting dysfunctional endothelial cells in reducing atherosclerosis. Int J Nanomed, 2019, 14:649-665.

9. Coutinho J, Middeldorp S, Stam J. Advances in the treatment of cerebral venous thrombosis. Curr Treat OptionsNeurol, 2014, 16(7): 299.

10. Sun B, Rui R, Pan H, et al. Effect of combined use of astragaloside IV (AsIV) and atorvastatin (AV) on expression of PPAR-y and inflammation-associated cytokines in atherosclerosis rats. Med Sci Monit, 2018, 24: 6229-6236.

11. Cao B, Bi G, Wang Y. Pharmacology of atorvastatin on myocardial ischemia-reperfusion in rats and drug effect analysis. Pak J Pharm Sci, 2019, 32(5 (special)): 2443-2447.

12. Zhu Z, Li J, Zhang X. Astragaloside IV protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation. Med Sci Monit, 2019, 25: 21322140.

13. Cai L, Zhang X, Hou M, et al. Natural flavone tricetin suppresses oxidized LDL-induced endol^helial inflammation mediated by Egr. Int Immunopharmacol, 2020, 80: 106224.

14. Wolf D, Ley K. Immunity and Inflammation in Athero- sclerosis. CircRes.2019, 124(2): 315-327.

15. Abela O, Ahsan C, Alreefi F, et al. Plaque rupture and thrombosis: the value of the atherosclerotic rabbit modll in defining the mechanism. Curr Atheroscler Rep, 2016, 18(6): 29.

16. Wang X, Cai X, Chen L, et al. The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI. Mediators Inflamm, 2015, 2015: 626934.

17. Shadab M, Millar MW, Slavin SA, et al. Autophagy protein ATG7 is a critical regulator of endothelial cell inflammation and permeability. Sti Rep, 2020, 10 (I): 13708.

18. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med.2014, 276(6): 618-632.

19. Tan C, Liu D, Yin J. Effects of clopidogrel combined with atorvastatin on platelets, hemorheology, D-Dimer and hs-CRP in patients with acute myocardial infarction. Journal of Zunyi Medical College, 2017, 40(1):68-71.

20. Deng Y, Zou W, Chen G, et al. Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease. Int JNeurosci, 2019, 129(11): 1133-1138.

21. Bot I, Jukema JW, Lankhuizen IM, et al. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis, 2011, 214(2): 295-300